Literature DB >> 40694

Binding characteristics of a major protein in rat ventral prostate cytosol that interacts with estramustine, a nitrogen mustard derivative of 17 beta-estradiol.

B Forsgren, J A Gustafsson, A Pousette, B Högberg.   

Abstract

The tissue distribution of [3H]estramustine, the dephosphorylated metabolite of estramustine phosphate (Estracyt), in the male rat was compared to that of [3H]estradiol 30 min and 2 hr following i.p. administration. In contrast to estradiol, estramustine was found to be efficiently concentrated in the ventral prostate gland by a soluble protein. The binding characteristics of this protein were studied in vitro using cytosol preparations of the gland. With a dextran-coated charcoal technique, the protein was found to bind estramustine with a broad pH optimum between pH 7 and pH 8.5, with an apparent Kd of 10 to 30 nM, and with a binding capacity of about 5 nmol/mg cytosol protein. The estramustine/protein complex was not retained by DNA-cellulose. None of the natural steroids tested inhibited the binding of 10 nM [3H]estramustine by more than 35% (progesterone), even when added in 4500-fold excess. The presence of a nitrogen mustard moiety at position 3 of the steroid was necessary for high-affinity binding to the protein. The protein was calculated to constitute about 20% of the total cytosol protein content.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 40694

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Production of monoclonal antibody against the C1 component of rat estramustine-binding protein: immunohistochemical study of rat prostate.

Authors:  Y Tamura; H Yuasa; T Suzuki; H Yamanaka; K Suzuki
Journal:  Histochem Cell Biol       Date:  1995-12       Impact factor: 4.304

2.  Prostatic steroid binding protein: organisation of C1 and C2 genes.

Authors:  M Parker; M Needham; R White; H Hurst; M Page
Journal:  Nucleic Acids Res       Date:  1982-09-11       Impact factor: 16.971

3.  Estramustine-binding protein in malignant glioma in rat.

Authors:  A E Karlsson; P Björk; A T Bergenheim; J Sandström; H Hedman; R Henriksson
Journal:  J Neurooncol       Date:  2000-08       Impact factor: 4.130

Review 4.  Pharmacokinetics and pharmacodynamics of estramustine phosphate.

Authors:  A T Bergenheim; R Henriksson
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

Review 5.  Estramustine in malignant glioma.

Authors:  A T Bergenheim; R Henriksson; J M Piepmeier; D Yoshida
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

6.  The hydrolysis of estramustine phosphate; in vitro studies.

Authors:  O Gunnarsson; S B Andersson; S A Johansson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983 Oct-Dec       Impact factor: 2.441

7.  Metabolism of estramustine phosphate (Estracyt) in patients with prostatic carcinoma.

Authors:  S B Andersson; P O Gunnarsson; T Nilsson; G P Forshell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

Review 8.  Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

Authors:  C M Perry; D McTavish
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

9.  Accumulation of estramustine and estromustine in adipose tissue of rats and humans.

Authors:  P O Gunnarsson; S B Andersson; A A Sandberg; M Ellman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer.

Authors:  F Boccardo; A Decensi; D Guarneri; G Martorana; C Giberti; L Giuliani
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.